Factor V Leiden Thrombophilia -- GeneReviews -- NCBI Bookshelf http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=factor...

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest. 2008; 133: 234S–256S. [PubMed]

Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the

leiden mutation: high prevalence in patients with abruptio placentae.
Am J Obstet Gynecol. 1998; 179: 1565–7. [PubMed]

Willems M, Sterneck M, Langer F, Jung R, Haddad M, Hagel C, Kuetemeier R, Eifrig B, Broering D,

Fischer L, Rogiers X. Recurrent deep-vein thrombosis based on homozygous factor V Leiden mutation
acquired after liver transplantation. Liver Transpl. 2003; 9: 870–3. [PubMed]

Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation

(Arg306-->Thr) associated with resistance to activated protein C. Blood. 1998; 91: 1140–4. [PubMed]

Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Brenkel I,
Regan L, Greer IA. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of
venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of
Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005; 94: 17–25. [PubMed]

Wuthrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691A)
mutation predisposes renal transplant recipients to thrombotic complications and graft loss.
Transplantation. 2001; 72: 549–50. [PubMed]

Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene
polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.
Lancet. 2006; 367: 651–8. [PubMed]

Young G, Albisetti M, Bonduel M, Brandao L, Chan A, Friedrichs F, Goldenberg NA, Grabowski E,

Heller C, Journeycake J, Kenet G, Krümpel A, Kurnik K, Lubetsky A, Male C, Manco-Johnson M,
Mathew P, Monagle P, van Ommen H, Simioni P, Svirin P, Tormene D, Nowak-Göttl U. Impact of
inherited thrombophilia on venous thromboembolism in children: a systematic review and
meta-analysis of observational studies. Circulation. 2008; 118: 1373–82. [PubMed]

Young G, Becker S, Düring C, Friedrichs F, Goldenberg N, Kenet G, Manco-Johnson M, Scheffold C,

Nowak-Göttl U. Influence of the factor II G20210A variant or the factor V G1691A mutation on
symptomatic recurrent venous thromboembolism in children: an international multicenter cohort
study. J Thromb Haemost. 2009; 7: 72–9. [PubMed]

Zammiti W, Mtiraoui N, Mercier E, Abboud N, Saidi S, Mahjoub T, Almawi WY, Gris JC. Association of
factor V gene polymorphisms (Leiden; Cambridge; Hong Kong and HR2 haplotype) with recurrent
idiopathic pregnancy loss in Tunisia. A case-control study. Thromb Haemost. 2006; 95: 612–7.
[PubMed]

Zenz W, Bodo Z, Plotho J, Streif W, Male C, Bernert G, Rauter L, Ebetsberger G, Kaltenbrunner K,

Kurnik P, Lischka A, Paky F, Ploier R, Hofler G, Mannhalter C, Muntean W. Factor V Leiden and
prothrombin gene G 20210 A variant in children with ischemic stroke.
Thromb Haemost. 1998; 80: 763–6. [PubMed]

Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single
genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997; 89: 397–402.
[PubMed]

Zoller B, Holm J, Svensson P, Dahlback B. Elevated levels of prothrombin activation fragment 1 + 2 in

plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance)
and/or inherited protein S deficiency. Thromb Haemost. 1996; 75: 270–4. [PubMed]

Published Statements and Policies Regarding Genetic Testing

47 of 48 4/9/2010 10:51 πµ